Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 79Lung Neoplasms 32Adenocarcinoma of Lung 13Adenocarcinoma, Bronchiolo-Alveolar 9Breast Neoplasms 8Neoplasm Metastasis 7Pancreatic Neoplasms 6Neoplasms 6Melanoma 6Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 5Esophageal Neoplasms 5Small Cell Lung Carcinoma 4Endometrial Neoplasms 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Urinary Bladder Neoplasms 3Pleural Effusion, Malignant 3Carcinoma, Renal Cell 3Thymoma 2Testicular Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Neoplasms, Unknown Primary 2Mouth Neoplasms 2Hypopharyngeal Neoplasms 2Head and Neck Neoplasms 2

Interventions

pembrolizumab 9Carboplatin 9Docetaxel 8Paclitaxel 6Nivolumab 6Cisplatin 5Gemcitabine 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4osimertinib 3fludarabine 3aldesleukin 3Radiotherapy 3Pemetrexed 3Erlotinib Hydrochloride 3Cyclophosphamide 3motexafin gadolinium 2figitumumab 2cemiplimab 2brigatinib 2atezolizumab 2alpha-2'-deoxythioguanosine 2Taxes 2Radiosurgery 2Ipilimumab 2Interleukin-2 2Crizotinib 2Bevacizumab 2vistusertib 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × Taxes × Thoracic × Clear all
NCT06561685 2026-04-20

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Eli Lilly and Company

Phase 1 Recruiting
340 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡